
Data as at 31 August 2024



IOHCM UK Growth Fund

Fund overview

- The Fund aims to generate long-term capital growth in excess of the FTSE All-Share Total Return Index through active management
- Fund managers Mark Costar and Vishal Bhatia seek to identify mispriced or undiscovered growth stocks with a perceived high margin of safety but significant upside potential
- A stock-picking fund that invests across the market cap range, albeit with a historic bias towards small-cap stocks
- SFDR classification: Article 8. Please click here for further details
- Benchmark: FTSE All-Share Total Return Index)
- The use of the Index does not limit the investment decisions of the fund manager therefore the shareholdings of the Fund may differ significantly from those of the Index
- Please refer to the Prospectus/KID for further information



Return history Annualised* 1m 3m 1vr 3vr 10vr X EUR Non-Dist 0.34 2.00 23.86 15.30 165.30 24.50 Benchmark 0.90 4.30 19.31 27.69 119.77 19.35

Discrete 12 month performance to end of August									
08.2	4 08.23	08.22	08.21	08.20	08.19	08.18	08.17	08.16	08.15
X EUR Non-Dist 23.8	6 10.07	-15.43	54.85	-	-	-	-	-	-

Past performance is no guarantee of future performance.

The value of an investment and the income from it can fall as well as rise as a result of market and currency fluctuations and you may not get back the amount originally invested. For further information on risks please refer to the Fund's KID and/or the Prospectus. The Fund's investment include shares in small-cap companies and these tend to be traded less frequently and in lower volumes than larger companies making them potentially less liquid and more volatile.

NAV of Share Class X in EUR, net income reinvested, net of fees. The X EUR Non-Distributing Class Class was launched on 19 March 2020. Performance of other share classes may vary and is available on request. *Annualised since launch.

Share class: X EUR Non-Dist ISIN: IE00BLLV8825

Fund details

Fund size EUR 233.83m Strategy size EUR 245.52m Launch date 6 November 2001 **Benchmark** FTSE All-Share TR

(12pm adjusted)

No. of holdings 55 **Domicile** Ireland **UCITS** Fund structure

Tax status UK reporting status

GRP Denominations

12pm Dublin time Valuation point

SFDR Article 8

Total strategy assets updated quarterly and shown as at 30 June 2024.

Fund managers



Mark Costar Senior Fund Manager

Mark has managed the Fund since launch. He joined JOHCM in 2001 and has 32 years of industry experience.



Vishal Bhatia Senior Fund Manager

Co-manager Vishal joined JOHCM in 2007 and has managed the Fund alongside Mark since 2011. He has 20 years of industry experience.

Contact details

Dealing & Investing

+353 1 434 5239

+353 1 553 9436

www.johcm.com Linked in







Portfolio analysis (%)

Data as at 31 August 2024

Active positions	
Top 10	Relative
Funding Circle Holdings Kooth BT Standard Chartered NCC Group Associated British Foods Rank PureTech Health Science in Sport BP	3.7 3.5 2.9 2.9 2.8 2.7 2.6 2.3 2.3
Bottom 10	Relative
AstraZeneca Unilever HSBC Shell GSK RELX British American Tobacco Diageo Rio Tinto London Stock Exchange	-3.1 -3.1 -3.0 -2.8 -2.7 -2.7 -2.3 -2.2 -2.1






FTSE Small = FTSE Small Cap, FTSE Fledgling and FTSE AIM

Attribution & contribution (%)

Stock attribution	
Top contributors	Relative return
Just Retirement	0.36
Science in Sport	0.19
Rolls-Royce	0.19
Shell	0.15
HSBC	0.14
Top detractors	
accesso	-0.38
Ebiquity	-0.36
Aquis Exchange	-0.30
Funding Circle Holdings	-0.25
GSK	-0.25



Please note that due to rounding breakdowns may not add to 100.00%. All Attribution figures are as at end of day and are calculated on a gross basis.

JOHCM UK Growth Fund



Fund manager's commentary

- August's market volatility, driven by a Nasdaq mini plunge and midcap weakness, highlighted fears of a US-led global slowdown, while AI investments surged without clear commercial traction, creating mispriced opportunities, especially in the UK
- Market mix effects were modestly negative, with notable underweight in healthcare.
 Stocks like Accesso and Aquis faced transitory setbacks, while Ebiquity's strategic concerns prompted engagement with the company for future management
- Science in Sport, NCC, and Rank Group delivered strong numbers, showcasing market leadership and impressive execution. These materially mispriced stocks present significant equity appreciation potential, leading to substantial portfolio positions

Back in the mists of time, August was a month for reflection and relaxation, a process very much aided by genteel and suitably accommodating markets. Those days have long gone. Each passing year seems to bring an increasing velocity of news flow, volatility and a frenzied rush to release results before the sunbeds get packed away for the season. It doesn't necessarily make for a more efficient market; indeed, evidence abounds of snap judgements on light volumes, but it is the practical reality, and in a hyper-connected world, it is going to stay that way. This time around, a Nasdaq mini plunge caught the eye, allied to persistent weakness in midcap & cyclical names at the expense of staples and defensives; the resurgence of the latter reflected increasing fears of a US led global slowdown. Meanwhile, AI didn't have a holiday either, with eye-watering capex cheques continuing to displace other budgets, a spend that is paradoxically leading to a soaring trajectory of breakthroughs but precious little evidence of commercial traction. Nvidia's results left the market none the wiser, leaving the debate to rumble on and sucking most of the air out of the room as it does so. Such a distortion to global allocations has its distractions, but a pleasing side effect is the plethora of mispriced opportunities it leaves elsewhere, and they are no more pronounced than in the UK.
uie un.

Market mix effects, as described above, were modestly negative, with the underweight in healthcare probably being the most notable. There were three specific stock distractors: Accesso, Aquis and Ebiquity. Although undeniably irritating, we would reasonably describe the first two of these as relatively small setbacks and largely transitory. Both have clear market leadership positions in their respective niches, a strong net cash position and a broad array of exciting medium-term growth optionality. In the fullness of time, we fully expect to make a strong return from both and continue to hold our positions. Indeed, we have added where appropriate. Ebiquity, on the other hand, was a bit more concerning and we are engaging with the company on the path forward. It is not a big position, but strategically, we have to accept our thesis here has been somewhat impaired and ensure that we manage this accordingly going forward.

Elsewhere, though, there were some very strong positives. The long-standing holding Just Group was particularly pleasing, and it produced barnstorming results that were substantially ahead of market forecasts. The release was characterised by strong progress across each of its key growth verticals, harvesting the benefits of its sustained investment in data and technology. Management has done an excellent job here, and the share price has started to respond accordingly. We have made some profit, but prospects continue to look very strong. Rolls Royce was another one to trounce estimates, with the cashflow particularly impressive and growth opportunities around datacentres in power systems and small module nuclear reactors (SMRs) coming increasingly into view. Others in the portfolio with strong numbers were Science in Sport, NCC and Rank Group. All three are yet more market leaders, executing impressively on their respective opportunities and looking increasingly (and very materially) mispriced; we have significant positions in each of these and see exciting scope for substantial equity appreciation.

Performance over 1 month	%
Fund - X EUR Non-Dist	0.34
Benchmark	0.90

Statistics

Annualised	d since launch		
Active share* (%)	75.78		
Fund volatility (%)	19.43		
Benchmark volatility (%)	19.87		
Alpha	9.04		
R squared	0.61		
Correlation	0.78		
Tracking error (%)	13.25		
Information ratio	0.39		
Sharpe ratio	1.15		

Data calculated weekly.

*The proportion of stock holdings in a fund's composition is different from the composition found in its benchmark. The greater the difference between the composition of the fund and its benchmark, the greater the active share.

Fund awards & ratings



Ratings and awards are as at 31 March 2024. © 2024 Morningstar, Inc. All rights reserved. Rating representative of the X EUR Non-Distributing Class, as at 30/06/2024. The information contained herein: (1) is proprietary to Morningstar; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results. This rating is 10% Analyst Driven and based on Data Coverage of 96%. For more detailed information about Morningstar's Medalist Rating, including its methodology, please see https://shareholders.morningstar.com/investor-relations/governance/Compliance--Disclosure/default.aspxSource: Sauren and FWW

JOHCM UK Growth Fund



Country registration

_	
	X EUR Non-D
Austria	\checkmark
Belgium	\checkmark
Denmark	\checkmark
Finland	\checkmark
France	\checkmark
Germany	\checkmark
Ireland	\checkmark
Italy	\checkmark
Jersey	\checkmark
Luxembourg	\checkmark
Netherlands	\checkmark
Norway	\checkmark
Singapore	\checkmark
Spain	\checkmark
Sweden	\checkmark
Switzerland	\checkmark
UK	\checkmark

Swiss representative and paying agent

Copies of the fund's current prospectus, key investor information document (KID) and financial statements can be obtained free of charge from the Swiss Representative, 1741 Fund Solutions Ltd., Burggraben 16, 9000 St. Gallen, Switzerland.

Share class details (Further details on additional share classes are available on request)

ISIN	SEDOL	Bloomberg	WKN	Initial charge	Annual charge	Ongoing charge	Minimum investment*
X EUR Non-Dist IE00BLLV8825	BLLV882	JOUKGXG ID	A2P1YM	Up to 5%	0.60%	0.68%	£100,000,000

Ongoing Charge is as at 30 August 2024. *Other currency equivalents apply.



Important information

Professional investors only.

Issued and approved in the UK by J O Hambro Capital Management Limited ("JOHCML") which is authorised and regulated by the Financial Conduct Authority. Registered office: Level 3, 1 St James's Market, London SW1Y 4AH. Issued in the European Union by Perpetual Investment Services Europe Limited ("PISEL") which is authorised by the Central Bank of Ireland. Registered office: 24 Fitzwilliam Place, Dublin 2, Ireland D02 T296. References to "JOHCM" below are to either JOHCML or PISEL as the context requires. Perpetual Group is a trading name of JOHCML and PISEL.

This is a marketing communication. Please refer to the fund prospectus and to the KIID / KID before making any final investment decisions.

These documents are available in English at www.johcm.com, and available from JOHCMI, or (for UK investors) JOHCML, at the addresses set out above. Information on the rights of investors can be found here

The distribution of this document in jurisdictions other than those referred to above may be restricted by law ("Restricted Jurisdictions"). Therefore this document is not intended for distribution in any Restricted Jurisdiction and should not be passed on or copied to any person in such a jurisdiction.

The registrations of the funds described in this document may be terminated by JOHCM at its discretion from time to time.

Notice to investors in Switzerland: The representative of the Company in Switzerland is 1741 Fund Solutions Ltd., Burggraben 16, 9000 St. Gallen, Switzerland (the "Representative"). The paying agent of the Company in Switzerland is Tellco Bank Ltd, Bahnhofstrasse 4, 6430 Schwyz, Switzerland. The Prospectus, the KIDs, the Instrument of Incorporation / the Constitution, and the annual and semi- annual reports may be obtained free of charge from the Representative. The Company is defined as J O Hambro Capital Management UK Umbrella Fund (domiciled in the UK), Perpetual Investment Services Europe ICAV (domiciled in Ireland) or Regnan Umbrella Fund ICAV (domiciled in Ireland), as relevant.

The investment promoted concerns the acquisition of shares in a fund and not the underlying assets.

Past performance is no guarantee of future performance. The value of an investment and the income from it can fall as well as rise as a result of market and currency fluctuations and you may not get back the amount originally invested.

Investments may include shares in small cap companies and these tend to be traded less frequently and in lower volumes than larger companies making them potentially less liquid and more volatile.

The information contained herein including any expression of opinion is for information purposes only and is given on the understanding that it is not a recommendation.

The information in this document does not constitute, or form part of, any offer to sell or issue, or any solicitation of an offer to purchase or subscribe for any funds or strategies described in this document; nor shall this document, or any part of it, or the fact of its distribution form the basis of, or be relied on, in connection with any contract.

Telephone calls to and from JOHCML and JOHCMI may be recorded. Information on how personal data is handled can be found in the JOHCM Privacy Statement on its website: www.johcm.com.

The registered mark J O Hambro® is owned by Barnham Broom Holdings Limited and is used under licence. JOHCM® is a registered trademark of JOHCML. Sources: JOHCM/Lipper/FTSE International (unless otherwise stated)

Source: FTSE International Limited ("FTSE") © FTSE 2024. The Industry Classification Benchmark ("ICB") and all rights in it are owned by and vest in FTSE and/or its licensors. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under licence. Neither FTSE, nor its licensors accept any liability for any errors or omissions in the ICB. No further distribution of ICB is permitted without FTSE's express written consent.